USP delays official effective dates of new and revised compounding standards

Sep 23, 2019 - 03:14 PM
compliance-deadline

The United States Pharmacopeia today notified stakeholders that it is postponing the official effective dates of several new and revised standards pertaining to pharmaceutical handling until further notice while it reviews appeals to the standards. Those standards include general chapters <795> (Pharmaceutical Compounding – Nonsterile Preparations), <797> (Pharmaceutical Compounding – Sterile Preparations), and <825> (Radiopharmaceuticals – Preparation, Compounding, Dispensing, and Repackaging). In addition, due to the pending appeals, USP new general chapter <800> (Hazardous Drugs Handling in Healthcare Settings) will remain official, but only informational and will not be applicable until the appeals process is complete. The AHA in November 2018 urged USP to delay the official dates of both USP <797> and <800> due to expedited implementation and compliance concerns.

Related News Articles

Headline
FDA issues early alert for heart pump controllers following 3 deaths, dozens of injuries 
The Food and Drug Administration has issued an early alert for all automated Impella controllers by Abiomed following an issue that has caused three deaths and…
Headline
Medical device supplier says cyber incident is disrupting some operations
Boston Scientific, a large supplier of medical devices, said in an Aug. 26 statement posted on its website that on Aug. 25 it “identified a cybersecurity…
Headline
FDA issues alert for certain Medline convenience kits 
The Food and Drug Administration has issued an early alert for specific lots of BD ChloraPrep Applicators by Medline because of a potential breach of sterility…
Headline
FDA recalls certain first aid kits with TRUE METRIX blood glucose devices 
The Food and Drug Administration has identified a Class I recall of North American Rescue first aid kits containing TRUE METRIX Blood Glucose Monitoring…
Headline
FDA says shortage of breast biopsy needles expected to last until 2027 
The Food and Drug Administration June 16 announced that a nationwide shortage of stereotactic breast biopsy needles is expected to last through the end of…
Blog
Sutter Health strengthens maternal care through innovation and connection
High-quality maternal care is essential to protecting the health of both mom and baby during birth.Sutter Health is taking a proactive, systemwide approach to…